AI assistant
NovoCure Ltd — Director's Dealing 2024
Feb 29, 2024
31949_dirs_2024-02-29_5ad0a832-9d37-4bd6-aa75-69673f7945e6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2024-02-27
Reporting Person: Leonard Frank X (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-27 | Ordinary Shares | A | 102249.00 | $16.30 | Acquired | 164695.00 | Direct |
| 2024-02-28 | Ordinary Shares | S | 2078.00 | $16.1428 | Disposed | 162617.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-27 | Stock Options (Right to buy) | $16.30 | A | 156348.00 | Acquired | 2034-02-26 | Ordinary Shares (156348.00) | Direct |
Footnotes
F1: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3: Options to buy 156,348 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.